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Abstract The more advantageous hepatitis C virus (HCV) inhibitors (most of them incorporating polysubstituted prolines
or pyrrolidines) are detailed in this paper. The improvement of current treatments by combination of antiviral
drugs is the driving force of this race to reduce the fast proliferation of this virus. The enhancement of efficiency
in short periods of treatment is crucial in the economical point of view and for the hope of all infected people.
New protease or polymerase inhibitors have been recently developed in order to substitute the traditional
highly toxic PEG-interferon α-2b/ribavirin tandem. The contribution of our group in this field concerns the
elaboration of the first and second generation GSK polymerase inhibitors through enantioselective processes
based on silver(I)- and gold(I)-catalyzed 1,3-dipolar cycloadditions of azomethine ylides.
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Résumé Dérivés de proline et pyrrolidine : de nouveaux candidats médicaments pour le traitement de
l’hépatite C
Cet article décrit les inhibiteurs du virus de l’hépatite C (VHC) les plus efficaces (la plupart incorporant des
prolines et pyrrolidines polysubstituées). L’amélioration des traitements actuels par une combinaison de
médicaments antiviraux est le moteur de cette course pour réduire la prolifération rapide du virus.
L’augmentation de l’efficacité sur de courtes périodes de traitement est cruciale du point de vue économique
et pour l’espoir des personnes infectées. De nouveaux inhibiteurs de la protéase ou de la polymérase ont
été récemment mis au point dans le but de remplacer le tandem traditionnel PEG-interféron α-2b/ribavirin
hautement toxique. La contribution de notre groupe dans ce domaine concerne l’élaboration des première
et seconde générations des inhibiteurs de polymérase GSK, grâce à des procédés énantiosélectifs basés
sur des cycloadditions 1,3-dipolaires d’ylures d’azométhine catalysés par de l’argent(I) et de l’or(I).
Mots-clés Proline, inhibiteur viral, virus de l’hépatite C, HCV, protéase, polymérase.epatitis C virus (HCV) is a blood-borne virus that has six
major genotypes [1]. It enters the body through direct
blood exposure and attacks cells in the liver where it
replicates. HCV causes liver inflammation and kills liver cells.
Up to 80% of people initially infected with HCV may become
chronically infected, that is, the infection does not clear up
within six months. The worst aspect of this silent virus is that
most people with chronic HCV do not have symptoms and
lead normal lives. However, in 10-25% of people with
chronic HCV, the disease progresses over a period of 10-
40 years and may lead to serious liver damage, cirrhosis
(scarring) and liver cancer. Today, for example, HCV is the
leading reason for liver transplants in the USA. There is
currently no vaccine or cure [2], but various treatments can
eradicate the virus and/or help slow or stop disease
progression for some people [3].
If we take in account that the two more extended global
virus infections namely human immunodeficiency virus (HIV,
40 millions approximately) and HCV (more than 200 millions)
are mainly transmitted by the same ways (blood to blood and
vertical), the risks of co-infection become another serious
problem. As many as 30% of people with HIV may also be
co-infected with hepatitis C virus [4].
Therapies against HCV development
Recombinant pegylated interferon α-2b (PEG-IFNα-2b)
[5], a HCV protease inhibitor, and ribavirin are pioneering
medications for treating hepatitis C (scheme 1). This com-
bined long range treatment resulted to be very expensive
with many secondary effects and a low percentage of
success (40-50% in genotype 1 infections).
Current research focuses on binary or ternary combina-
tions. They are tested and evaluated in both phase II and III
levels. The main component of this cocktail is PEG-IFNα-2b,
which maintains a more constant level of interferon in the
blood and better reduces the ability of HCV to replicate. Rib-
avirin, as second component, is a highly toxic oral medica-
tion used in combination with interferon to treat this infection,
so alternative molecules are designed. The third component
is an HCV protease or polymerase inhibitor that acts as a
direct-acting antiviral agent (DAAA) inhibiting the replication
process of the hepatitis C virus [6]. Ribavirin and HCV DAAA,
for example, are not effective when used alone and frequent-
ly require the presence of PEG-IFNα-2b.
These DAAAs target specific key steps of the viral life
cycle. They inhibit the HCV protease or the HCV polymerase.
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themselves due to the high levels of resistance caused by
the fast HCV mutations.
At this moment, people infected by HCV genotype 1 who
take the triple combination have up to a 91% chance of cur-
ing hepatitis C according to some particular phase III trials.
Treatment can be tailored to 24, 36 or 48 weeks total treat-
ment duration. People with HCV genotype 2 or 3 are typically
treated with a combination of pegylated interferon plus riba-
virin (without an HCV protease inhibitor). In this case, the
chances of being cured are up to 82%. Total treatment dura-
tion is usually 24 weeks. An alternative to the remaining 18%
of non-cured infected people is based on a triple combina-
tion as described above.
The most common side effects of interferon, ribavirin and
an HCV protease inhibitor include mild flu-like symptoms,
muscle and joint pain, nausea, headaches, fatigue, loss of
appetite, dry skin, anxiety, depression and insomnia. For
some people, physical side effects are worse when the drug
is started and may diminish over time. The most common
reason for stopping HCV therapy is anemia (low red blood
cells count), thrombocytopenia (low platelet count), and
neutropenia (low white blood cells count).
New DAAA drugs [7]
These new medications supplement – not replace – the
traditional treatment by blocking specific sites of the corre-
sponding viral proteins according to known structure-activity
relationships (SAR). Phase IV (commercially available) and
phase III protease inhibitors (scheme 2 and table) incorpo-
rate a proline or a pyrrolidine nucleus except cyclopeptide
DEBio025. Proline or proline derivatives are very important
natural and synthetic compounds with very interesting
chemical and bioactive applications. They are mainly useful
in SAR studies of themselves or proteins/synthetic mole-
cules containing them [8-9], in the synthesis of pyrrolidine
core-based natural products and other applications in many
scientific fields.
The triple combination of PEG-IFNα-2b/ribavirin/telapre-
vir is the most efficient and shorter approved treatment
(requires 12 weeks) unlike to other combinations incorporat-
ing boceprevir (28-48 weeks) or BMS-790052 (24 weeks).
Polymerase inhibitors are not as developed as protease
ones such as it is demonstrated by the latest results obtained
in several clinical stages. Most promising polymerase
blockers DEBio025 (indirect blocker) and GS7977 are going
to reach the market very soon (scheme 3). Whilst DEBio025
is an immunosuppresor acting on cyclophilin-B, a binding
protein that plays a role in hepatitis C virus (HCV) replication,
Gilead made a big wager on the uracil nucleotide analogue
GS7977 because it has been considered as the first all oral
treatment for the hepatitis C [10]. But at this moment,
GS7977 with PEG-IFNα-2b/ribavirin cures most treatment-
naive hepatitis C patients in 12 weeks.
There are dozens of compounds in the pipeline waiting
for FDA approval but many of them failed in whatever part of
this long and difficult way of drugs. For example, the very
promising in vivo results of proline-core antiviral agent
GSK 625433 terminated earlier after phase I trials (November
2011) (scheme 4) [6].
Scheme 1 - PEG-interferon-α-2b and ribavirin, two key components
of the therapy against hepatitis C virus.
a 
b 
Scheme 2 - a) Phase IV (commercially available) protease inhibitors,
and b) phase III protease inhibitors.
Table - Name and status of the most promising DAAA drugs acting
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polyWe developed in our group the asymmetric synthesis of
the first and second generation antiviral drugs by 1,3-dipolar
cycloaddition (as key-step) between the corresponding
methyl iminoleucinate and tert-butyl acrylate employing a
chiral phosphoramidite-AgClO4 [11] (scheme 5a) and a chiral
dimeric binap-gold(I) complex [12] (scheme 5b), respectively.
In both routes, the overall yields obtained were moderate to
good and enantioselectivities very high, especially in the
case of the second generation inhibitor (99% ee). In this
moment, the synthetic approach of the third generation
GSK 625433 polymerase inhibitor, much more active than
the previous first and second ones, is currently underway.
Now, risks of hepatitis C became more serious when
appear as co-infection in people with HIV. It is estimated
that approximately 1.2 million people in the USA are infect-
ed with HIV and more than 4 million are infected with hepa-
titis C as well. The different treatments (36-44-50 weeks) in
phases III-IV are based on the possible multiple combina-
tion of PEG-IFNα-2b/ribavirin, and one of the DAAA drugs
depicted in the table.
As summary, the hope of cure of infected patients is
getting higher and higher and new effective drugs with more
reduced side effects are envisaged. Nucleotide derived
agents are demonstrated to be more resistant to mutations
of this virus responsible of the hepatitis C. The search for the
ideal single drug (not combined with other antivirals), whose
smaller dose is able to reduce completely the infection with
negligible side effects, is the main objective of scientists.
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